nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—hematologic cancer	0.0967	0.54	CbGaD
Gefitinib—MKNK2—Ruxolitinib—hematologic cancer	0.0565	0.114	CbGbCtD
Gefitinib—ALB—hematologic cancer	0.0422	0.235	CbGaD
Gefitinib—ABCB1—hematologic cancer	0.0402	0.225	CbGaD
Gefitinib—ERBB3—Dasatinib—hematologic cancer	0.0383	0.0773	CbGbCtD
Gefitinib—IRAK1—Ruxolitinib—hematologic cancer	0.0325	0.0655	CbGbCtD
Gefitinib—HIPK4—Imatinib—hematologic cancer	0.0305	0.0615	CbGbCtD
Gefitinib—EPHA6—Nilotinib—hematologic cancer	0.0277	0.0559	CbGbCtD
Gefitinib—MAP2K5—Nilotinib—hematologic cancer	0.0227	0.0457	CbGbCtD
Gefitinib—MAP3K19—Ruxolitinib—hematologic cancer	0.0216	0.0436	CbGbCtD
Gefitinib—MAP2K5—Dasatinib—hematologic cancer	0.02	0.0404	CbGbCtD
Gefitinib—MAP3K19—Dasatinib—hematologic cancer	0.0184	0.0371	CbGbCtD
Gefitinib—ABCG2—Clofarabine—hematologic cancer	0.0101	0.0203	CbGbCtD
Gefitinib—ORM1—Imatinib—hematologic cancer	0.00741	0.015	CbGbCtD
Gefitinib—CYP1A1—Methoxsalen—hematologic cancer	0.00599	0.0121	CbGbCtD
Gefitinib—ABCG2—Daunorubicin—hematologic cancer	0.00591	0.0119	CbGbCtD
Gefitinib—CYP1A1—Bortezomib—hematologic cancer	0.0057	0.0115	CbGbCtD
Gefitinib—CYP1A1—Daunorubicin—hematologic cancer	0.00545	0.011	CbGbCtD
Gefitinib—ABCG2—Teniposide—hematologic cancer	0.00513	0.0104	CbGbCtD
Gefitinib—CYP1A1—Thalidomide—hematologic cancer	0.00497	0.01	CbGbCtD
Gefitinib—ABCG2—Cladribine—hematologic cancer	0.00492	0.00993	CbGbCtD
Gefitinib—ABCG2—Imatinib—hematologic cancer	0.00452	0.00913	CbGbCtD
Gefitinib—CYP1A1—Dacarbazine—hematologic cancer	0.00427	0.00862	CbGbCtD
Gefitinib—ABCG2—Nilotinib—hematologic cancer	0.00411	0.0083	CbGbCtD
Gefitinib—CYP2C9—Bexarotene—hematologic cancer	0.00374	0.00755	CbGbCtD
Gefitinib—ABCG2—Dasatinib—hematologic cancer	0.00363	0.00733	CbGbCtD
Gefitinib—ABCB1—Lenalidomide—hematologic cancer	0.00363	0.00733	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—hematologic cancer	0.00359	0.00724	CbGbCtD
Gefitinib—CYP1A1—Dasatinib—hematologic cancer	0.00335	0.00677	CbGbCtD
Gefitinib—CYP3A5—Daunorubicin—hematologic cancer	0.00327	0.0066	CbGbCtD
Gefitinib—CYP2D6—Lomustine—hematologic cancer	0.00318	0.00642	CbGbCtD
Gefitinib—ALB—Imatinib—hematologic cancer	0.00312	0.00629	CbGbCtD
Gefitinib—CYP2C9—Idarubicin—hematologic cancer	0.0031	0.00626	CbGbCtD
Gefitinib—CYP3A5—Thalidomide—hematologic cancer	0.00298	0.00601	CbGbCtD
Gefitinib—CYP3A5—Teniposide—hematologic cancer	0.00284	0.00574	CbGbCtD
Gefitinib—CYP2D6—Idarubicin—hematologic cancer	0.00284	0.00572	CbGbCtD
Gefitinib—ABCG2—Irinotecan—hematologic cancer	0.00283	0.0057	CbGbCtD
Gefitinib—CYP2C19—Bortezomib—hematologic cancer	0.00276	0.00557	CbGbCtD
Gefitinib—CYP3A5—Ifosfamide—hematologic cancer	0.00262	0.0053	CbGbCtD
Gefitinib—CYP3A5—Imatinib—hematologic cancer	0.00251	0.00506	CbGbCtD
Gefitinib—ABCG2—Vincristine—hematologic cancer	0.00247	0.00498	CbGbCtD
Gefitinib—CYP2D6—Hydroxyurea—hematologic cancer	0.00241	0.00487	CbGbCtD
Gefitinib—CYP2C19—Thalidomide—hematologic cancer	0.0024	0.00485	CbGbCtD
Gefitinib—ABCG2—Cisplatin—hematologic cancer	0.0023	0.00465	CbGbCtD
Gefitinib—CYP2C9—Bortezomib—hematologic cancer	0.00229	0.00463	CbGbCtD
Gefitinib—CYP2C19—Teniposide—hematologic cancer	0.00229	0.00463	CbGbCtD
Gefitinib—ABCG2—Etoposide—hematologic cancer	0.00226	0.00457	CbGbCtD
Gefitinib—CYP3A4—Bexarotene—hematologic cancer	0.00218	0.00439	CbGbCtD
Gefitinib—ABCB1—Daunorubicin—hematologic cancer	0.00213	0.0043	CbGbCtD
Gefitinib—CYP2C19—Ifosfamide—hematologic cancer	0.00212	0.00427	CbGbCtD
Gefitinib—CYP2D6—Bortezomib—hematologic cancer	0.0021	0.00423	CbGbCtD
Gefitinib—ABCB1—Alitretinoin—hematologic cancer	0.00209	0.00421	CbGbCtD
Gefitinib—ALB—Prednisone—hematologic cancer	0.00205	0.00415	CbGbCtD
Gefitinib—CYP3A4—Lomustine—hematologic cancer	0.00202	0.00408	CbGbCtD
Gefitinib—CYP3A4—Busulfan—hematologic cancer	0.00202	0.00408	CbGbCtD
Gefitinib—CYP2C19—Imatinib—hematologic cancer	0.00202	0.00408	CbGbCtD
Gefitinib—CYP3A5—Dasatinib—hematologic cancer	0.00201	0.00406	CbGbCtD
Gefitinib—CYP2C9—Thalidomide—hematologic cancer	0.002	0.00403	CbGbCtD
Gefitinib—ALB—Irinotecan—hematologic cancer	0.00195	0.00393	CbGbCtD
Gefitinib—CYP2C9—Teniposide—hematologic cancer	0.00191	0.00385	CbGbCtD
Gefitinib—ABCG2—Dexamethasone—hematologic cancer	0.00186	0.00376	CbGbCtD
Gefitinib—CYP3A4—Thiotepa—hematologic cancer	0.0018	0.00364	CbGbCtD
Gefitinib—CYP2C9—Ifosfamide—hematologic cancer	0.00176	0.00355	CbGbCtD
Gefitinib—CYP1A1—Dexamethasone—hematologic cancer	0.00172	0.00347	CbGbCtD
Gefitinib—CYP2C9—Imatinib—hematologic cancer	0.00168	0.00339	CbGbCtD
Gefitinib—ABCB1—Imatinib—hematologic cancer	0.00163	0.00329	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—hematologic cancer	0.00157	0.00316	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—hematologic cancer	0.00154	0.00312	CbGbCtD
Gefitinib—CYP2D6—Imatinib—hematologic cancer	0.00154	0.0031	CbGbCtD
Gefitinib—CYP2C9—Nilotinib—hematologic cancer	0.00153	0.00308	CbGbCtD
Gefitinib—ABCG2—Methotrexate—hematologic cancer	0.0015	0.00302	CbGbCtD
Gefitinib—ABCB1—Nilotinib—hematologic cancer	0.00148	0.00299	CbGbCtD
Gefitinib—ABCB1—Vinorelbine—hematologic cancer	0.00147	0.00297	CbGbCtD
Gefitinib—CYP3A4—Methoxsalen—hematologic cancer	0.0014	0.00283	CbGbCtD
Gefitinib—HIPK4—gonad—hematologic cancer	0.0014	0.0289	CbGeAlD
Gefitinib—CYP2D6—Nilotinib—hematologic cancer	0.0014	0.00282	CbGbCtD
Gefitinib—CYP2D6—Vinorelbine—hematologic cancer	0.00139	0.0028	CbGbCtD
Gefitinib—CYP3A5—Vincristine—hematologic cancer	0.00137	0.00276	CbGbCtD
Gefitinib—CYP3A4—Bortezomib—hematologic cancer	0.00133	0.00269	CbGbCtD
Gefitinib—CYP2C19—Prednisone—hematologic cancer	0.00133	0.00269	CbGbCtD
Gefitinib—ABCB1—Dasatinib—hematologic cancer	0.00131	0.00264	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—hematologic cancer	0.00129	0.00261	CbGbCtD
Gefitinib—CYP3A4—Daunorubicin—hematologic cancer	0.00128	0.00258	CbGbCtD
Gefitinib—CYP3A5—Etoposide—hematologic cancer	0.00125	0.00253	CbGbCtD
Gefitinib—SBK1—blood—hematologic cancer	0.00124	0.0255	CbGeAlD
Gefitinib—ABCB1—Betamethasone—hematologic cancer	0.00115	0.00233	CbGbCtD
Gefitinib—ABCB1—Gemcitabine—hematologic cancer	0.00114	0.00231	CbGbCtD
Gefitinib—ABCB1—Prednisolone—hematologic cancer	0.00114	0.0023	CbGbCtD
Gefitinib—CYP3A4—Cytarabine—hematologic cancer	0.00113	0.00227	CbGbCtD
Gefitinib—CYP3A4—Teniposide—hematologic cancer	0.00111	0.00224	CbGbCtD
Gefitinib—EPHA6—gonad—hematologic cancer	0.00111	0.0228	CbGeAlD
Gefitinib—CHEK2—blood—hematologic cancer	0.00108	0.0222	CbGeAlD
Gefitinib—ABCB1—Prednisone—hematologic cancer	0.00107	0.00217	CbGbCtD
Gefitinib—CHEK2—bone marrow—hematologic cancer	0.00104	0.0215	CbGeAlD
Gefitinib—CYP3A5—Dexamethasone—hematologic cancer	0.00103	0.00208	CbGbCtD
Gefitinib—ALB—Methotrexate—hematologic cancer	0.00103	0.00208	CbGbCtD
Gefitinib—CYP3A4—Ifosfamide—hematologic cancer	0.00102	0.00206	CbGbCtD
Gefitinib—SBK1—testis—hematologic cancer	0.00102	0.0211	CbGeAlD
Gefitinib—ABCB1—Irinotecan—hematologic cancer	0.00102	0.00206	CbGbCtD
Gefitinib—IRAK4—hematopoietic system—hematologic cancer	0.00101	0.0209	CbGeAlD
Gefitinib—HIPK4—testis—hematologic cancer	0.00101	0.0208	CbGeAlD
Gefitinib—ERBB3—hematopoietic system—hematologic cancer	0.000994	0.0205	CbGeAlD
Gefitinib—CYP3A4—Imatinib—hematologic cancer	0.000977	0.00197	CbGbCtD
Gefitinib—MKNK2—hematopoietic system—hematologic cancer	0.000945	0.0195	CbGeAlD
Gefitinib—IRAK1—hematopoietic system—hematologic cancer	0.000945	0.0195	CbGeAlD
Gefitinib—CHEK2—lung—hematologic cancer	0.000943	0.0194	CbGeAlD
Gefitinib—MKNK1—hematopoietic system—hematologic cancer	0.000933	0.0192	CbGeAlD
Gefitinib—CYP3A4—Ruxolitinib—hematologic cancer	0.00092	0.00186	CbGbCtD
Gefitinib—ABCB1—Vinblastine—hematologic cancer	0.000906	0.00183	CbGbCtD
Gefitinib—ABCB1—Vincristine—hematologic cancer	0.000891	0.0018	CbGbCtD
Gefitinib—CHEK2—testis—hematologic cancer	0.00089	0.0183	CbGeAlD
Gefitinib—CYP3A4—Nilotinib—hematologic cancer	0.000888	0.00179	CbGbCtD
Gefitinib—CYP3A4—Vinorelbine—hematologic cancer	0.000881	0.00178	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—hematologic cancer	0.000856	0.00173	CbGbCtD
Gefitinib—CYP2D6—Vinblastine—hematologic cancer	0.000854	0.00172	CbGbCtD
Gefitinib—CYP2C19—Dexamethasone—hematologic cancer	0.000832	0.00168	CbGbCtD
Gefitinib—ABCB1—Cisplatin—hematologic cancer	0.000831	0.00168	CbGbCtD
Gefitinib—ABCB1—Etoposide—hematologic cancer	0.000816	0.00165	CbGbCtD
Gefitinib—CYP3A4—Triamcinolone—hematologic cancer	0.000806	0.00163	CbGbCtD
Gefitinib—EPHA6—testis—hematologic cancer	0.000798	0.0165	CbGeAlD
Gefitinib—CYP3A4—Dasatinib—hematologic cancer	0.000785	0.00158	CbGbCtD
Gefitinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000775	0.00156	CbGbCtD
Gefitinib—MAP3K19—lung—hematologic cancer	0.000769	0.0158	CbGeAlD
Gefitinib—STK10—hematopoietic system—hematologic cancer	0.000768	0.0158	CbGeAlD
Gefitinib—SBK1—lymph node—hematologic cancer	0.000741	0.0153	CbGeAlD
Gefitinib—MAP3K19—testis—hematologic cancer	0.000726	0.015	CbGeAlD
Gefitinib—MKNK2—gonad—hematologic cancer	0.000718	0.0148	CbGeAlD
Gefitinib—MKNK1—gonad—hematologic cancer	0.000709	0.0146	CbGeAlD
Gefitinib—CYP2C9—Dexamethasone—hematologic cancer	0.000691	0.0014	CbGbCtD
Gefitinib—CYP3A4—Betamethasone—hematologic cancer	0.000691	0.00139	CbGbCtD
Gefitinib—CSNK1E—blood—hematologic cancer	0.000682	0.0141	CbGeAlD
Gefitinib—CYP3A4—Prednisolone—hematologic cancer	0.000682	0.00138	CbGbCtD
Gefitinib—IRAK4—blood—hematologic cancer	0.000672	0.0138	CbGeAlD
Gefitinib—ABCB1—Dexamethasone—hematologic cancer	0.000671	0.00135	CbGbCtD
Gefitinib—IRAK4—bone marrow—hematologic cancer	0.00065	0.0134	CbGeAlD
Gefitinib—CHEK2—lymph node—hematologic cancer	0.000645	0.0133	CbGeAlD
Gefitinib—CYP3A4—Prednisone—hematologic cancer	0.000644	0.0013	CbGbCtD
Gefitinib—CYP2D6—Dexamethasone—hematologic cancer	0.000632	0.00128	CbGbCtD
Gefitinib—MKNK2—blood—hematologic cancer	0.000626	0.0129	CbGeAlD
Gefitinib—IRAK1—blood—hematologic cancer	0.000626	0.0129	CbGeAlD
Gefitinib—EGFR—lung—hematologic cancer	0.000622	0.0128	CbGeAlD
Gefitinib—MKNK1—blood—hematologic cancer	0.000618	0.0127	CbGeAlD
Gefitinib—CYP3A4—Irinotecan—hematologic cancer	0.00061	0.00123	CbGbCtD
Gefitinib—MKNK2—bone marrow—hematologic cancer	0.000606	0.0125	CbGeAlD
Gefitinib—IRAK1—bone marrow—hematologic cancer	0.000606	0.0125	CbGeAlD
Gefitinib—CSNK1E—lung—hematologic cancer	0.000598	0.0123	CbGeAlD
Gefitinib—MKNK1—bone marrow—hematologic cancer	0.000598	0.0123	CbGeAlD
Gefitinib—IRAK4—lung—hematologic cancer	0.000589	0.0121	CbGeAlD
Gefitinib—EGFR—testis—hematologic cancer	0.000587	0.0121	CbGeAlD
Gefitinib—STK10—gonad—hematologic cancer	0.000584	0.012	CbGeAlD
Gefitinib—ERBB3—lung—hematologic cancer	0.000577	0.0119	CbGeAlD
Gefitinib—CSNK1E—testis—hematologic cancer	0.000564	0.0116	CbGeAlD
Gefitinib—ORM1—hematopoietic system—hematologic cancer	0.000557	0.0115	CbGeAlD
Gefitinib—ABCB1—Doxorubicin—hematologic cancer	0.000557	0.00112	CbGbCtD
Gefitinib—IRAK4—testis—hematologic cancer	0.000556	0.0114	CbGeAlD
Gefitinib—MKNK2—lung—hematologic cancer	0.000549	0.0113	CbGeAlD
Gefitinib—IRAK1—lung—hematologic cancer	0.000549	0.0113	CbGeAlD
Gefitinib—ERBB3—testis—hematologic cancer	0.000545	0.0112	CbGeAlD
Gefitinib—CYP3A4—Vinblastine—hematologic cancer	0.000543	0.0011	CbGbCtD
Gefitinib—MKNK1—lung—hematologic cancer	0.000542	0.0112	CbGeAlD
Gefitinib—ABCB1—Methotrexate—hematologic cancer	0.000539	0.00109	CbGbCtD
Gefitinib—CYP3A4—Vincristine—hematologic cancer	0.000534	0.00108	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—hematologic cancer	0.000524	0.00106	CbGbCtD
Gefitinib—MKNK2—testis—hematologic cancer	0.000518	0.0107	CbGeAlD
Gefitinib—IRAK1—testis—hematologic cancer	0.000518	0.0107	CbGeAlD
Gefitinib—MKNK1—testis—hematologic cancer	0.000511	0.0105	CbGeAlD
Gefitinib—STK10—blood—hematologic cancer	0.000509	0.0105	CbGeAlD
Gefitinib—STK10—bone marrow—hematologic cancer	0.000493	0.0101	CbGeAlD
Gefitinib—CYP3A4—Etoposide—hematologic cancer	0.000489	0.000987	CbGbCtD
Gefitinib—MAP2K5—blood—hematologic cancer	0.000455	0.00937	CbGeAlD
Gefitinib—STK10—lung—hematologic cancer	0.000446	0.00919	CbGeAlD
Gefitinib—EGFR—lymph node—hematologic cancer	0.000425	0.00877	CbGeAlD
Gefitinib—STK10—testis—hematologic cancer	0.000421	0.00868	CbGeAlD
Gefitinib—CSNK1E—lymph node—hematologic cancer	0.000409	0.00843	CbGeAlD
Gefitinib—IRAK4—lymph node—hematologic cancer	0.000403	0.0083	CbGeAlD
Gefitinib—CYP3A4—Dexamethasone—hematologic cancer	0.000402	0.000811	CbGbCtD
Gefitinib—MAP2K5—lung—hematologic cancer	0.000399	0.00821	CbGeAlD
Gefitinib—ERBB3—lymph node—hematologic cancer	0.000395	0.00813	CbGeAlD
Gefitinib—CYP2C19—hematopoietic system—hematologic cancer	0.000393	0.0081	CbGeAlD
Gefitinib—Erlotinib—JAK3—hematologic cancer	0.000384	0.0715	CrCbGaD
Gefitinib—MAP2K5—testis—hematologic cancer	0.000376	0.00775	CbGeAlD
Gefitinib—MKNK2—lymph node—hematologic cancer	0.000375	0.00773	CbGeAlD
Gefitinib—IRAK1—lymph node—hematologic cancer	0.000375	0.00773	CbGeAlD
Gefitinib—MKNK1—lymph node—hematologic cancer	0.000371	0.00764	CbGeAlD
Gefitinib—ORM1—blood—hematologic cancer	0.000369	0.0076	CbGeAlD
Gefitinib—ORM1—bone marrow—hematologic cancer	0.000357	0.00736	CbGeAlD
Gefitinib—Afatinib—LCK—hematologic cancer	0.000351	0.0652	CrCbGaD
Gefitinib—CYP3A4—Doxorubicin—hematologic cancer	0.000334	0.000673	CbGbCtD
Gefitinib—ORM1—lung—hematologic cancer	0.000324	0.00667	CbGeAlD
Gefitinib—CYP1A1—hematopoietic system—hematologic cancer	0.000317	0.00653	CbGeAlD
Gefitinib—CYP3A5—hematopoietic system—hematologic cancer	0.00031	0.00638	CbGeAlD
Gefitinib—STK10—lymph node—hematologic cancer	0.000305	0.00629	CbGeAlD
Gefitinib—CYP2C9—hematopoietic system—hematologic cancer	0.000305	0.00628	CbGeAlD
Gefitinib—Erlotinib—FLT3—hematologic cancer	0.000291	0.0542	CrCbGaD
Gefitinib—CHEK2—Nilotinib—Imatinib—hematologic cancer	0.00029	0.104	CbGdCrCtD
Gefitinib—Bosutinib—BCR—hematologic cancer	0.000279	0.0518	CrCbGaD
Gefitinib—Bosutinib—EIF2AK1—hematologic cancer	0.000279	0.0518	CrCbGaD
Gefitinib—MAP2K5—lymph node—hematologic cancer	0.000273	0.00562	CbGeAlD
Gefitinib—ALB—testis—hematologic cancer	0.000268	0.00552	CbGeAlD
Gefitinib—CYP2C19—blood—hematologic cancer	0.000261	0.00537	CbGeAlD
Gefitinib—Erlotinib—ABL2—hematologic cancer	0.00026	0.0483	CrCbGaD
Gefitinib—Bosutinib—SYK—hematologic cancer	0.000237	0.044	CrCbGaD
Gefitinib—CYP3A4—hematopoietic system—hematologic cancer	0.000233	0.00479	CbGeAlD
Gefitinib—CYP2D6—hematopoietic system—hematologic cancer	0.000229	0.00471	CbGeAlD
Gefitinib—CHEK2—Ponatinib—Nilotinib—hematologic cancer	0.000224	0.0801	CbGdCrCtD
Gefitinib—ORM1—lymph node—hematologic cancer	0.000221	0.00456	CbGeAlD
Gefitinib—ABCG2—blood—hematologic cancer	0.000221	0.00456	CbGeAlD
Gefitinib—ABCG2—bone marrow—hematologic cancer	0.000214	0.00441	CbGeAlD
Gefitinib—CYP1A1—blood—hematologic cancer	0.00021	0.00433	CbGeAlD
Gefitinib—CYP3A5—blood—hematologic cancer	0.000205	0.00423	CbGeAlD
Gefitinib—CYP2C9—blood—hematologic cancer	0.000202	0.00416	CbGeAlD
Gefitinib—ALB—lymph node—hematologic cancer	0.000194	0.004	CbGeAlD
Gefitinib—ABCG2—lung—hematologic cancer	0.000194	0.00399	CbGeAlD
Gefitinib—Bosutinib—CDK2—hematologic cancer	0.000193	0.0359	CrCbGaD
Gefitinib—Vandetanib—FLT3—hematologic cancer	0.000192	0.0357	CrCbGaD
Gefitinib—CYP1A1—lung—hematologic cancer	0.000184	0.00379	CbGeAlD
Gefitinib—ABCG2—testis—hematologic cancer	0.000183	0.00377	CbGeAlD
Gefitinib—ERBB3—Podofilox—Teniposide—hematologic cancer	0.000181	0.0645	CbGdCrCtD
Gefitinib—CYP3A5—lung—hematologic cancer	0.00018	0.00371	CbGeAlD
Gefitinib—Bosutinib—BTK—hematologic cancer	0.000179	0.0334	CrCbGaD
Gefitinib—Bosutinib—TXK—hematologic cancer	0.000179	0.0334	CrCbGaD
Gefitinib—Vandetanib—ABL2—hematologic cancer	0.000171	0.0318	CrCbGaD
Gefitinib—CHEK2—Ponatinib—Imatinib—hematologic cancer	0.00017	0.0607	CbGdCrCtD
Gefitinib—ABCB1—hematopoietic system—hematologic cancer	0.000165	0.00339	CbGeAlD
Gefitinib—Afatinib—ABL1—hematologic cancer	0.000164	0.0305	CrCbGaD
Gefitinib—Vandetanib—LCK—hematologic cancer	0.000163	0.0303	CrCbGaD
Gefitinib—Bosutinib—ABL2—hematologic cancer	0.00016	0.0297	CrCbGaD
Gefitinib—CYP3A4—blood—hematologic cancer	0.000154	0.00317	CbGeAlD
Gefitinib—Bosutinib—LCK—hematologic cancer	0.000153	0.0284	CrCbGaD
Gefitinib—CYP2D6—blood—hematologic cancer	0.000152	0.00312	CbGeAlD
Gefitinib—Vandetanib—FGR—hematologic cancer	0.000145	0.027	CrCbGaD
Gefitinib—CHEK2—Vindesine—Vinorelbine—hematologic cancer	0.000144	0.0514	CbGdCrCtD
Gefitinib—Bosutinib—MAP2K1—hematologic cancer	0.000136	0.0253	CrCbGaD
Gefitinib—Bosutinib—FGR—hematologic cancer	0.000136	0.0253	CrCbGaD
Gefitinib—ABCG2—lymph node—hematologic cancer	0.000133	0.00273	CbGeAlD
Gefitinib—CYP1A1—lymph node—hematologic cancer	0.000126	0.00259	CbGeAlD
Gefitinib—CYP2D6—testis—hematologic cancer	0.000125	0.00258	CbGeAlD
Gefitinib—ABCB1—gonad—hematologic cancer	0.000125	0.00258	CbGeAlD
Gefitinib—Vandetanib—RET—hematologic cancer	0.000124	0.023	CrCbGaD
Gefitinib—CHEK2—Podofilox—Teniposide—hematologic cancer	0.000122	0.0436	CbGdCrCtD
Gefitinib—Erlotinib—ABL1—hematologic cancer	0.000116	0.0216	CrCbGaD
Gefitinib—CHEK2—Vindesine—Vincristine—hematologic cancer	0.000115	0.0411	CbGdCrCtD
Gefitinib—CHEK2—Vindesine—Vinblastine—hematologic cancer	0.000115	0.0411	CbGdCrCtD
Gefitinib—ABCB1—blood—hematologic cancer	0.000109	0.00225	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Daunorubicin—hematologic cancer	0.000109	0.0389	CbGdCrCtD
Gefitinib—CHEK2—Doxorubicin—Daunorubicin—hematologic cancer	0.000109	0.0389	CbGdCrCtD
Gefitinib—ERBB3—Podofilox—Etoposide—hematologic cancer	0.000107	0.0384	CbGdCrCtD
Gefitinib—ABCB1—bone marrow—hematologic cancer	0.000106	0.00217	CbGeAlD
Gefitinib—Bosutinib—ALK—hematologic cancer	9.69e-05	0.018	CrCbGaD
Gefitinib—ABCB1—lung—hematologic cancer	9.56e-05	0.00197	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vinorelbine—hematologic cancer	9.25e-05	0.033	CbGdCrCtD
Gefitinib—Bosutinib—CSF1R—hematologic cancer	9.19e-05	0.0171	CrCbGaD
Gefitinib—Erlotinib—UGT1A1—hematologic cancer	9.17e-05	0.017	CrCbGaD
Gefitinib—ABCB1—testis—hematologic cancer	9.02e-05	0.00186	CbGeAlD
Gefitinib—Vandetanib—PDGFRB—hematologic cancer	8.57e-05	0.0159	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Idarubicin—hematologic cancer	8.25e-05	0.0294	CbGdCrCtD
Gefitinib—CHEK2—Epirubicin—Idarubicin—hematologic cancer	8.25e-05	0.0294	CbGdCrCtD
Gefitinib—Bosutinib—PDGFRB—hematologic cancer	8.02e-05	0.0149	CrCbGaD
Gefitinib—CHEK2—Vincristine—Vinorelbine—hematologic cancer	7.77e-05	0.0277	CbGdCrCtD
Gefitinib—Vandetanib—ABL1—hematologic cancer	7.64e-05	0.0142	CrCbGaD
Gefitinib—ERBB3—Vinblastine—Vincristine—hematologic cancer	7.4e-05	0.0264	CbGdCrCtD
Gefitinib—Afatinib—ABCG2—hematologic cancer	7.29e-05	0.0136	CrCbGaD
Gefitinib—CHEK2—Vinorelbine—Vincristine—hematologic cancer	7.27e-05	0.0259	CbGdCrCtD
Gefitinib—CHEK2—Vinorelbine—Vinblastine—hematologic cancer	7.27e-05	0.0259	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—hematologic cancer	7.26e-05	0.0259	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—hematologic cancer	7.26e-05	0.0259	CbGdCrCtD
Gefitinib—Bosutinib—ABL1—hematologic cancer	7.15e-05	0.0133	CrCbGaD
Gefitinib—Vandetanib—SRC—hematologic cancer	6.91e-05	0.0129	CrCbGaD
Gefitinib—ABCB1—lymph node—hematologic cancer	6.54e-05	0.00135	CbGeAlD
Gefitinib—Bosutinib—SRC—hematologic cancer	6.47e-05	0.012	CrCbGaD
Gefitinib—CHEK2—Vinblastine—Vinorelbine—hematologic cancer	6.25e-05	0.0223	CbGdCrCtD
Gefitinib—CHEK2—Vincristine—Vinblastine—hematologic cancer	6.21e-05	0.0222	CbGdCrCtD
Gefitinib—Vandetanib—VEGFA—hematologic cancer	5.51e-05	0.0102	CrCbGaD
Gefitinib—Erlotinib—ABCG2—hematologic cancer	5.15e-05	0.00958	CrCbGaD
Gefitinib—CHEK2—Vinblastine—Vincristine—hematologic cancer	5e-05	0.0178	CbGdCrCtD
Gefitinib—Lapatinib—ABCB1—hematologic cancer	4.28e-05	0.00796	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—hematologic cancer	3.79e-05	0.0135	CbGdCrCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—hematologic cancer	3.5e-05	0.0125	CbGdCrCtD
Gefitinib—Vandetanib—ABCG2—hematologic cancer	3.39e-05	0.00631	CrCbGaD
Gefitinib—Afatinib—ABCB1—hematologic cancer	3.04e-05	0.00564	CrCbGaD
Gefitinib—CSNK1E—Danazol—Prednisone—hematologic cancer	2.47e-05	0.00882	CbGdCrCtD
Gefitinib—Erlotinib—ALB—hematologic cancer	2.25e-05	0.00418	CrCbGaD
Gefitinib—Erlotinib—ABCB1—hematologic cancer	2.14e-05	0.00399	CrCbGaD
Gefitinib—Dyspnoea—Triamcinolone—hematologic cancer	1.89e-05	0.000126	CcSEcCtD
Gefitinib—Rash—Alitretinoin—hematologic cancer	1.89e-05	0.000126	CcSEcCtD
Gefitinib—Nervous system disorder—Betamethasone—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Nervous system disorder—Dexamethasone—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Dermatitis—Alitretinoin—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Thrombocytopenia—Dexamethasone—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Thrombocytopenia—Betamethasone—hematologic cancer	1.88e-05	0.000126	CcSEcCtD
Gefitinib—Vomiting—Ifosfamide—hematologic cancer	1.88e-05	0.000125	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—hematologic cancer	1.88e-05	0.000125	CcSEcCtD
Gefitinib—Angioedema—Prednisone—hematologic cancer	1.87e-05	0.000125	CcSEcCtD
Gefitinib—Diarrhoea—Gemcitabine—hematologic cancer	1.87e-05	0.000125	CcSEcCtD
Gefitinib—Nausea—Thalidomide—hematologic cancer	1.87e-05	0.000125	CcSEcCtD
Gefitinib—Rash—Ifosfamide—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Gefitinib—Dermatitis—Ifosfamide—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—hematologic cancer	1.86e-05	0.000124	CcSEcCtD
Gefitinib—Urticaria—Etoposide—hematologic cancer	1.85e-05	0.000124	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—hematologic cancer	1.85e-05	0.000124	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—hematologic cancer	1.85e-05	0.000124	CcSEcCtD
Gefitinib—Malaise—Prednisone—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—hematologic cancer	1.85e-05	0.000123	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—hematologic cancer	1.84e-05	0.000123	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—hematologic cancer	1.84e-05	0.000123	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—hematologic cancer	1.84e-05	0.000123	CcSEcCtD
Gefitinib—Vomiting—Vincristine—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Anorexia—Betamethasone—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Anorexia—Dexamethasone—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Fatigue—Triamcinolone—hematologic cancer	1.83e-05	0.000122	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—hematologic cancer	1.82e-05	0.000121	CcSEcCtD
Gefitinib—Rash—Vincristine—hematologic cancer	1.82e-05	0.000121	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—hematologic cancer	1.82e-05	0.000121	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Gefitinib—Pain—Triamcinolone—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—hematologic cancer	1.81e-05	0.000121	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Gefitinib—Hypotension—Betamethasone—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Gefitinib—Hypotension—Dexamethasone—hematologic cancer	1.8e-05	0.00012	CcSEcCtD
Gefitinib—Nausea—Carmustine—hematologic cancer	1.79e-05	0.00012	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—hematologic cancer	1.79e-05	0.00012	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—hematologic cancer	1.79e-05	0.000119	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—hematologic cancer	1.78e-05	0.000119	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—hematologic cancer	1.78e-05	0.000119	CcSEcCtD
Gefitinib—Nausea—Alitretinoin—hematologic cancer	1.78e-05	0.000119	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Gefitinib—Rash—Irinotecan—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—hematologic cancer	1.77e-05	0.000118	CcSEcCtD
Gefitinib—Nausea—Ifosfamide—hematologic cancer	1.76e-05	0.000117	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—hematologic cancer	1.74e-05	0.000116	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—hematologic cancer	1.74e-05	0.000116	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—hematologic cancer	1.74e-05	0.000116	CcSEcCtD
Gefitinib—Vomiting—Gemcitabine—hematologic cancer	1.74e-05	0.000116	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.73e-05	0.000116	CcSEcCtD
Gefitinib—Rash—Gemcitabine—hematologic cancer	1.72e-05	0.000115	CcSEcCtD
Gefitinib—Dermatitis—Gemcitabine—hematologic cancer	1.72e-05	0.000115	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—hematologic cancer	1.72e-05	0.000115	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—hematologic cancer	1.72e-05	0.000115	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Gefitinib—Nausea—Vincristine—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—hematologic cancer	1.71e-05	0.000114	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—hematologic cancer	1.7e-05	0.000114	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—hematologic cancer	1.7e-05	0.000114	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Betamethasone—hematologic cancer	1.7e-05	0.00607	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Dexamethasone—hematologic cancer	1.7e-05	0.00607	CbGdCrCtD
Gefitinib—Hypersensitivity—Prednisolone—hematologic cancer	1.7e-05	0.000113	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Gefitinib—Urticaria—Triamcinolone—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Gefitinib—Asthenia—Etoposide—hematologic cancer	1.68e-05	0.000112	CcSEcCtD
Gefitinib—Body temperature increased—Triamcinolone—hematologic cancer	1.67e-05	0.000112	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—hematologic cancer	1.67e-05	0.000112	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—hematologic cancer	1.67e-05	0.000112	CcSEcCtD
Gefitinib—Decreased appetite—Dexamethasone—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Gefitinib—Decreased appetite—Betamethasone—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Gefitinib—Nausea—Irinotecan—hematologic cancer	1.67e-05	0.000111	CcSEcCtD
Gefitinib—Infection—Prednisone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Triamcinolone—hematologic cancer	1.66e-05	0.00593	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Triamcinolone—hematologic cancer	1.66e-05	0.00593	CbGdCrCtD
Gefitinib—Mediastinal disorder—Epirubicin—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—Fatigue—Betamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—Fatigue—Dexamethasone—hematologic cancer	1.66e-05	0.000111	CcSEcCtD
Gefitinib—Pruritus—Etoposide—hematologic cancer	1.65e-05	0.00011	CcSEcCtD
Gefitinib—Shock—Prednisone—hematologic cancer	1.65e-05	0.00011	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—hematologic cancer	1.65e-05	0.00011	CcSEcCtD
Gefitinib—Pain—Betamethasone—hematologic cancer	1.64e-05	0.00011	CcSEcCtD
Gefitinib—Pain—Dexamethasone—hematologic cancer	1.64e-05	0.00011	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—hematologic cancer	1.64e-05	0.00011	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—hematologic cancer	1.63e-05	0.000109	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—hematologic cancer	1.63e-05	0.000108	CcSEcCtD
Gefitinib—Nausea—Gemcitabine—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—hematologic cancer	1.62e-05	0.000108	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—hematologic cancer	1.61e-05	0.000108	CcSEcCtD
Gefitinib—Rash—Cisplatin—hematologic cancer	1.61e-05	0.000107	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—hematologic cancer	1.61e-05	0.000107	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—hematologic cancer	1.6e-05	0.000107	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—hematologic cancer	1.6e-05	0.000107	CcSEcCtD
Gefitinib—Anorexia—Prednisone—hematologic cancer	1.6e-05	0.000106	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—hematologic cancer	1.59e-05	0.000106	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—hematologic cancer	1.58e-05	0.000106	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—hematologic cancer	1.58e-05	0.000106	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—hematologic cancer	1.58e-05	0.00563	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—hematologic cancer	1.58e-05	0.00563	CbGdCrCtD
Gefitinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.57e-05	0.000105	CcSEcCtD
Gefitinib—Gastrointestinal pain—Betamethasone—hematologic cancer	1.57e-05	0.000105	CcSEcCtD
Gefitinib—Hypersensitivity—Triamcinolone—hematologic cancer	1.56e-05	0.000104	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—hematologic cancer	1.55e-05	0.000103	CcSEcCtD
Gefitinib—Malaise—Methotrexate—hematologic cancer	1.55e-05	0.000103	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—hematologic cancer	1.54e-05	0.0055	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—hematologic cancer	1.54e-05	0.0055	CbGdCrCtD
Gefitinib—Mediastinal disorder—Doxorubicin—hematologic cancer	1.54e-05	0.000103	CcSEcCtD
Gefitinib—Urticaria—Betamethasone—hematologic cancer	1.53e-05	0.000102	CcSEcCtD
Gefitinib—Urticaria—Dexamethasone—hematologic cancer	1.53e-05	0.000102	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—hematologic cancer	1.52e-05	0.000102	CcSEcCtD
Gefitinib—Asthenia—Triamcinolone—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Gefitinib—Abdominal pain—Dexamethasone—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Gefitinib—Body temperature increased—Dexamethasone—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Gefitinib—Body temperature increased—Betamethasone—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Gefitinib—Abdominal pain—Betamethasone—hematologic cancer	1.52e-05	0.000101	CcSEcCtD
Gefitinib—Nausea—Cisplatin—hematologic cancer	1.51e-05	0.000101	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—hematologic cancer	1.51e-05	0.000101	CcSEcCtD
Gefitinib—Pruritus—Triamcinolone—hematologic cancer	1.5e-05	0.0001	CcSEcCtD
Gefitinib—Cough—Methotrexate—hematologic cancer	1.5e-05	9.98e-05	CcSEcCtD
Gefitinib—Vomiting—Etoposide—hematologic cancer	1.48e-05	9.91e-05	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—hematologic cancer	1.48e-05	9.9e-05	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—hematologic cancer	1.48e-05	9.89e-05	CcSEcCtD
Gefitinib—Vandetanib—ALB—hematologic cancer	1.48e-05	0.00275	CrCbGaD
Gefitinib—Rash—Etoposide—hematologic cancer	1.47e-05	9.83e-05	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—hematologic cancer	1.47e-05	9.82e-05	CcSEcCtD
Gefitinib—Decreased appetite—Prednisone—hematologic cancer	1.45e-05	9.71e-05	CcSEcCtD
Gefitinib—Rash—Prednisolone—hematologic cancer	1.45e-05	9.69e-05	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—hematologic cancer	1.45e-05	9.68e-05	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.45e-05	9.67e-05	CcSEcCtD
Gefitinib—Malaise—Epirubicin—hematologic cancer	1.45e-05	9.65e-05	CcSEcCtD
Gefitinib—Fatigue—Prednisone—hematologic cancer	1.44e-05	9.63e-05	CcSEcCtD
Gefitinib—Constipation—Prednisone—hematologic cancer	1.43e-05	9.55e-05	CcSEcCtD
Gefitinib—Cough—Epirubicin—hematologic cancer	1.4e-05	9.34e-05	CcSEcCtD
Gefitinib—Infection—Methotrexate—hematologic cancer	1.39e-05	9.27e-05	CcSEcCtD
Gefitinib—Nausea—Etoposide—hematologic cancer	1.39e-05	9.26e-05	CcSEcCtD
Gefitinib—Asthenia—Dexamethasone—hematologic cancer	1.38e-05	9.2e-05	CcSEcCtD
Gefitinib—Asthenia—Betamethasone—hematologic cancer	1.38e-05	9.2e-05	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—hematologic cancer	1.37e-05	9.15e-05	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—hematologic cancer	1.37e-05	9.15e-05	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—hematologic cancer	1.37e-05	9.14e-05	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—hematologic cancer	1.37e-05	9.13e-05	CcSEcCtD
Gefitinib—Nausea—Prednisolone—hematologic cancer	1.37e-05	9.13e-05	CcSEcCtD
Gefitinib—Pruritus—Betamethasone—hematologic cancer	1.36e-05	9.07e-05	CcSEcCtD
Gefitinib—Pruritus—Dexamethasone—hematologic cancer	1.36e-05	9.07e-05	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—hematologic cancer	1.36e-05	9.07e-05	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.36e-05	9.05e-05	CcSEcCtD
Gefitinib—Vomiting—Triamcinolone—hematologic cancer	1.35e-05	8.99e-05	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—hematologic cancer	1.34e-05	8.93e-05	CcSEcCtD
Gefitinib—Rash—Triamcinolone—hematologic cancer	1.34e-05	8.91e-05	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—hematologic cancer	1.34e-05	8.91e-05	CcSEcCtD
Gefitinib—Dermatitis—Triamcinolone—hematologic cancer	1.33e-05	8.9e-05	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—hematologic cancer	1.33e-05	8.9e-05	CcSEcCtD
Gefitinib—Urticaria—Prednisone—hematologic cancer	1.33e-05	8.87e-05	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—hematologic cancer	1.32e-05	8.83e-05	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—hematologic cancer	1.32e-05	8.83e-05	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—hematologic cancer	1.32e-05	0.00246	CrCbGaD
Gefitinib—Diarrhoea—Betamethasone—hematologic cancer	1.31e-05	8.78e-05	CcSEcCtD
Gefitinib—Diarrhoea—Dexamethasone—hematologic cancer	1.31e-05	8.78e-05	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—hematologic cancer	1.31e-05	8.72e-05	CcSEcCtD
Gefitinib—Infection—Epirubicin—hematologic cancer	1.3e-05	8.68e-05	CcSEcCtD
Gefitinib—Cough—Doxorubicin—hematologic cancer	1.29e-05	8.64e-05	CcSEcCtD
Gefitinib—Shock—Epirubicin—hematologic cancer	1.29e-05	8.59e-05	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—hematologic cancer	1.28e-05	8.57e-05	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—hematologic cancer	1.28e-05	8.55e-05	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—hematologic cancer	1.27e-05	8.48e-05	CcSEcCtD
Gefitinib—CHEK2—Danazol—Prednisone—hematologic cancer	1.26e-05	0.00451	CbGdCrCtD
Gefitinib—Nausea—Triamcinolone—hematologic cancer	1.26e-05	8.4e-05	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.25e-05	8.37e-05	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—hematologic cancer	1.25e-05	8.33e-05	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—hematologic cancer	1.25e-05	8.32e-05	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—hematologic cancer	1.24e-05	8.25e-05	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—hematologic cancer	1.23e-05	8.23e-05	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—hematologic cancer	1.22e-05	8.16e-05	CcSEcCtD
Gefitinib—Vomiting—Dexamethasone—hematologic cancer	1.22e-05	8.15e-05	CcSEcCtD
Gefitinib—Vomiting—Betamethasone—hematologic cancer	1.22e-05	8.15e-05	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—hematologic cancer	1.22e-05	8.11e-05	CcSEcCtD
Gefitinib—Rash—Dexamethasone—hematologic cancer	1.21e-05	8.09e-05	CcSEcCtD
Gefitinib—Rash—Betamethasone—hematologic cancer	1.21e-05	8.09e-05	CcSEcCtD
Gefitinib—Dermatitis—Betamethasone—hematologic cancer	1.21e-05	8.08e-05	CcSEcCtD
Gefitinib—Dermatitis—Dexamethasone—hematologic cancer	1.21e-05	8.08e-05	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.21e-05	8.06e-05	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—hematologic cancer	1.21e-05	8.05e-05	CcSEcCtD
Gefitinib—Infection—Doxorubicin—hematologic cancer	1.2e-05	8.03e-05	CcSEcCtD
Gefitinib—Asthenia—Prednisone—hematologic cancer	1.2e-05	8.01e-05	CcSEcCtD
Gefitinib—Pain—Methotrexate—hematologic cancer	1.2e-05	7.98e-05	CcSEcCtD
Gefitinib—Shock—Doxorubicin—hematologic cancer	1.19e-05	7.95e-05	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—hematologic cancer	1.19e-05	7.93e-05	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—hematologic cancer	1.19e-05	7.91e-05	CcSEcCtD
Gefitinib—Pruritus—Prednisone—hematologic cancer	1.18e-05	7.9e-05	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—hematologic cancer	1.18e-05	7.85e-05	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—hematologic cancer	1.17e-05	7.79e-05	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—hematologic cancer	1.15e-05	7.7e-05	CcSEcCtD
Gefitinib—Diarrhoea—Prednisone—hematologic cancer	1.14e-05	7.64e-05	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—hematologic cancer	1.14e-05	7.63e-05	CcSEcCtD
Gefitinib—Nausea—Betamethasone—hematologic cancer	1.14e-05	7.62e-05	CcSEcCtD
Gefitinib—Nausea—Dexamethasone—hematologic cancer	1.14e-05	7.62e-05	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—hematologic cancer	1.14e-05	7.59e-05	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—hematologic cancer	1.13e-05	7.55e-05	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.13e-05	7.54e-05	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—hematologic cancer	1.13e-05	7.53e-05	CcSEcCtD
Gefitinib—Pain—Epirubicin—hematologic cancer	1.12e-05	7.47e-05	CcSEcCtD
Gefitinib—Constipation—Epirubicin—hematologic cancer	1.12e-05	7.47e-05	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—hematologic cancer	1.11e-05	7.42e-05	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—hematologic cancer	1.11e-05	7.38e-05	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—hematologic cancer	1.11e-05	7.38e-05	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—hematologic cancer	1.08e-05	7.21e-05	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—hematologic cancer	1.07e-05	7.14e-05	CcSEcCtD
Gefitinib—Vomiting—Prednisone—hematologic cancer	1.06e-05	7.1e-05	CcSEcCtD
Gefitinib—Rash—Prednisone—hematologic cancer	1.06e-05	7.04e-05	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—hematologic cancer	1.05e-05	7.04e-05	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—hematologic cancer	1.05e-05	7.03e-05	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.05e-05	6.98e-05	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—hematologic cancer	1.04e-05	6.97e-05	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—hematologic cancer	1.04e-05	6.94e-05	CcSEcCtD
Gefitinib—Pain—Doxorubicin—hematologic cancer	1.04e-05	6.91e-05	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—hematologic cancer	1.04e-05	6.91e-05	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—hematologic cancer	1.03e-05	6.91e-05	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—hematologic cancer	1.03e-05	6.91e-05	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—hematologic cancer	1.03e-05	6.88e-05	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—hematologic cancer	1e-05	6.7e-05	CcSEcCtD
Gefitinib—Nausea—Prednisone—hematologic cancer	9.94e-06	6.63e-05	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	9.9e-06	6.61e-05	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—hematologic cancer	9.89e-06	6.6e-05	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—hematologic cancer	9.64e-06	6.44e-05	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—hematologic cancer	9.62e-06	6.42e-05	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—hematologic cancer	9.57e-06	6.39e-05	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—hematologic cancer	9.57e-06	6.39e-05	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—hematologic cancer	9.57e-06	6.39e-05	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—hematologic cancer	9.39e-06	6.27e-05	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—hematologic cancer	9.26e-06	6.18e-05	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—hematologic cancer	8.95e-06	5.98e-05	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—hematologic cancer	8.92e-06	5.95e-05	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—hematologic cancer	8.89e-06	5.93e-05	CcSEcCtD
Gefitinib—Rash—Methotrexate—hematologic cancer	8.82e-06	5.89e-05	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—hematologic cancer	8.81e-06	5.88e-05	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—hematologic cancer	8.69e-06	5.8e-05	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—hematologic cancer	8.57e-06	5.72e-05	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—hematologic cancer	8.32e-06	5.55e-05	CcSEcCtD
Gefitinib—Nausea—Methotrexate—hematologic cancer	8.31e-06	5.54e-05	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—hematologic cancer	8.29e-06	5.53e-05	CcSEcCtD
Gefitinib—Rash—Epirubicin—hematologic cancer	8.25e-06	5.51e-05	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—hematologic cancer	8.24e-06	5.5e-05	CcSEcCtD
Gefitinib—Nausea—Epirubicin—hematologic cancer	7.77e-06	5.19e-05	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—hematologic cancer	7.7e-06	5.14e-05	CcSEcCtD
Gefitinib—Rash—Doxorubicin—hematologic cancer	7.64e-06	5.1e-05	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—hematologic cancer	7.63e-06	5.09e-05	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—hematologic cancer	7.19e-06	4.8e-05	CcSEcCtD
Gefitinib—EGFR—Immune System—EP300—hematologic cancer	8.46e-07	7.11e-06	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—hematologic cancer	8.44e-07	7.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—hematologic cancer	8.43e-07	7.09e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.4e-07	7.07e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—hematologic cancer	8.39e-07	7.06e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK8—hematologic cancer	8.39e-07	7.06e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—hematologic cancer	8.33e-07	7e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—hematologic cancer	8.29e-07	6.98e-06	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—hematologic cancer	8.29e-07	6.97e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—hematologic cancer	8.28e-07	6.96e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	8.26e-07	6.94e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—hematologic cancer	8.25e-07	6.94e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREB1—hematologic cancer	8.24e-07	6.93e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—hematologic cancer	8.22e-07	6.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—hematologic cancer	8.21e-07	6.9e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—hematologic cancer	8.21e-07	6.9e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYCS—hematologic cancer	8.19e-07	6.89e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—hematologic cancer	8.19e-07	6.89e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—hematologic cancer	8.18e-07	6.88e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—hematologic cancer	8.14e-07	6.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	8.14e-07	6.84e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYCS—hematologic cancer	8.12e-07	6.83e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—hematologic cancer	8.08e-07	6.79e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	8.07e-07	6.79e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—hematologic cancer	8.07e-07	6.78e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6R—hematologic cancer	8.04e-07	6.76e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NCOR1—hematologic cancer	8.03e-07	6.76e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—hematologic cancer	8.03e-07	6.76e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	8.03e-07	6.76e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CRABP1—hematologic cancer	8.03e-07	6.76e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREBBP—hematologic cancer	8.03e-07	6.75e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3R1—hematologic cancer	8.03e-07	6.75e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.96e-07	6.7e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—hematologic cancer	7.95e-07	6.69e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—hematologic cancer	7.93e-07	6.67e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—hematologic cancer	7.91e-07	6.66e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—hematologic cancer	7.91e-07	6.65e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—hematologic cancer	7.85e-07	6.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX5—hematologic cancer	7.83e-07	6.58e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—hematologic cancer	7.81e-07	6.57e-06	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—hematologic cancer	7.79e-07	6.55e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—hematologic cancer	7.79e-07	6.55e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—hematologic cancer	7.75e-07	6.51e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—hematologic cancer	7.67e-07	6.45e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAP2K1—hematologic cancer	7.66e-07	6.45e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—hematologic cancer	7.66e-07	6.44e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—hematologic cancer	7.65e-07	6.43e-06	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—hematologic cancer	7.64e-07	6.43e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—hematologic cancer	7.61e-07	6.4e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.59e-07	6.39e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—hematologic cancer	7.59e-07	6.39e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NUP98—hematologic cancer	7.58e-07	6.38e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—hematologic cancer	7.58e-07	6.37e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—hematologic cancer	7.54e-07	6.34e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—hematologic cancer	7.48e-07	6.29e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—hematologic cancer	7.45e-07	6.27e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—hematologic cancer	7.43e-07	6.25e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—hematologic cancer	7.41e-07	6.23e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADCY7—hematologic cancer	7.36e-07	6.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA3—hematologic cancer	7.36e-07	6.19e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—hematologic cancer	7.33e-07	6.16e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—hematologic cancer	7.32e-07	6.16e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NUP214—hematologic cancer	7.31e-07	6.15e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—hematologic cancer	7.31e-07	6.14e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—hematologic cancer	7.29e-07	6.13e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF2—hematologic cancer	7.29e-07	6.13e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—hematologic cancer	7.27e-07	6.11e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.26e-07	6.11e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—hematologic cancer	7.22e-07	6.07e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NCOR1—hematologic cancer	7.21e-07	6.07e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—hematologic cancer	7.21e-07	6.07e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3R1—hematologic cancer	7.19e-07	6.05e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTR—hematologic cancer	7.16e-07	6.02e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	7.16e-07	6.02e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—hematologic cancer	7.16e-07	6.02e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—hematologic cancer	7.13e-07	5.99e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—hematologic cancer	7.11e-07	5.98e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—hematologic cancer	7.1e-07	5.97e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NCOR1—hematologic cancer	7.04e-07	5.92e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—hematologic cancer	7.04e-07	5.92e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—hematologic cancer	7.03e-07	5.91e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—hematologic cancer	7.02e-07	5.91e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—hematologic cancer	7e-07	5.88e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JAK2—hematologic cancer	6.99e-07	5.88e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—hematologic cancer	6.97e-07	5.87e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—hematologic cancer	6.93e-07	5.83e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.92e-07	5.82e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—hematologic cancer	6.87e-07	5.78e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.86e-07	5.77e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—hematologic cancer	6.85e-07	5.76e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—hematologic cancer	6.83e-07	5.75e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—hematologic cancer	6.82e-07	5.74e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—hematologic cancer	6.81e-07	5.73e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.81e-07	5.73e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—hematologic cancer	6.8e-07	5.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—hematologic cancer	6.79e-07	5.71e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—hematologic cancer	6.77e-07	5.7e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—hematologic cancer	6.72e-07	5.65e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—hematologic cancer	6.68e-07	5.61e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SDC1—hematologic cancer	6.66e-07	5.6e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—hematologic cancer	6.65e-07	5.59e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—hematologic cancer	6.64e-07	5.58e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—hematologic cancer	6.64e-07	5.58e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—hematologic cancer	6.63e-07	5.58e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NCOR1—hematologic cancer	6.63e-07	5.58e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—hematologic cancer	6.58e-07	5.54e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NCOR1—hematologic cancer	6.58e-07	5.53e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—hematologic cancer	6.58e-07	5.53e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—hematologic cancer	6.55e-07	5.5e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—hematologic cancer	6.43e-07	5.41e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—hematologic cancer	6.42e-07	5.4e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—hematologic cancer	6.4e-07	5.38e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—hematologic cancer	6.37e-07	5.36e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—hematologic cancer	6.36e-07	5.35e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—hematologic cancer	6.34e-07	5.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—hematologic cancer	6.29e-07	5.29e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.26e-07	5.26e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—hematologic cancer	6.26e-07	5.26e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	6.23e-07	5.24e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—hematologic cancer	6.22e-07	5.23e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	6.16e-07	5.18e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—hematologic cancer	6.11e-07	5.14e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—hematologic cancer	6.1e-07	5.13e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—hematologic cancer	6.09e-07	5.13e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—hematologic cancer	6.09e-07	5.12e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—hematologic cancer	6.07e-07	5.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—hematologic cancer	6.06e-07	5.1e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—hematologic cancer	6.05e-07	5.09e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—hematologic cancer	6.01e-07	5.06e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—hematologic cancer	5.97e-07	5.02e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—hematologic cancer	5.94e-07	5e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—hematologic cancer	5.94e-07	4.99e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—hematologic cancer	5.93e-07	4.99e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—hematologic cancer	5.86e-07	4.93e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—hematologic cancer	5.85e-07	4.92e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—hematologic cancer	5.81e-07	4.89e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—hematologic cancer	5.79e-07	4.87e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—hematologic cancer	5.78e-07	4.86e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—hematologic cancer	5.75e-07	4.84e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3R1—hematologic cancer	5.75e-07	4.84e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	5.75e-07	4.83e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—hematologic cancer	5.73e-07	4.82e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—hematologic cancer	5.68e-07	4.78e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD44—hematologic cancer	5.66e-07	4.76e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NQO1—hematologic cancer	5.66e-07	4.76e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.62e-07	4.72e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—hematologic cancer	5.62e-07	4.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK8—hematologic cancer	5.61e-07	4.72e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—hematologic cancer	5.6e-07	4.71e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—hematologic cancer	5.59e-07	4.71e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—hematologic cancer	5.54e-07	4.66e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—hematologic cancer	5.53e-07	4.65e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—hematologic cancer	5.47e-07	4.6e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3R1—hematologic cancer	5.43e-07	4.57e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—hematologic cancer	5.36e-07	4.51e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	5.36e-07	4.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYCS—hematologic cancer	5.35e-07	4.5e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—hematologic cancer	5.34e-07	4.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.32e-07	4.48e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—hematologic cancer	5.32e-07	4.47e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—hematologic cancer	5.31e-07	4.46e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—hematologic cancer	5.24e-07	4.41e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	5.23e-07	4.4e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—hematologic cancer	5.18e-07	4.36e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—hematologic cancer	5.13e-07	4.31e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.12e-07	4.31e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—hematologic cancer	5.12e-07	4.3e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—hematologic cancer	5.12e-07	4.3e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—hematologic cancer	5.11e-07	4.3e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—hematologic cancer	5.02e-07	4.22e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—hematologic cancer	4.97e-07	4.18e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3R1—hematologic cancer	4.95e-07	4.17e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—hematologic cancer	4.94e-07	4.16e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	4.93e-07	4.14e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—hematologic cancer	4.9e-07	4.12e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	4.88e-07	4.11e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—hematologic cancer	4.85e-07	4.08e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—hematologic cancer	4.77e-07	4.01e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—hematologic cancer	4.75e-07	4e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.72e-07	3.97e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—hematologic cancer	4.72e-07	3.97e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	4.71e-07	3.96e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—hematologic cancer	4.65e-07	3.91e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	4.6e-07	3.87e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—hematologic cancer	4.59e-07	3.86e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—hematologic cancer	4.57e-07	3.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—hematologic cancer	4.57e-07	3.84e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—hematologic cancer	4.54e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—hematologic cancer	4.53e-07	3.81e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	4.52e-07	3.8e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.47e-07	3.76e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	4.45e-07	3.74e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—hematologic cancer	4.4e-07	3.7e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—hematologic cancer	4.37e-07	3.68e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	4.34e-07	3.65e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.34e-07	3.65e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.34e-07	3.65e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—hematologic cancer	4.33e-07	3.64e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	4.33e-07	3.64e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	4.29e-07	3.61e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—hematologic cancer	4.28e-07	3.6e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—hematologic cancer	4.24e-07	3.56e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—hematologic cancer	4.13e-07	3.48e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	4.1e-07	3.45e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	4.09e-07	3.44e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	4.05e-07	3.41e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	4.05e-07	3.4e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	4.01e-07	3.37e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—hematologic cancer	3.95e-07	3.32e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—hematologic cancer	3.91e-07	3.29e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.83e-07	3.22e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	3.77e-07	3.17e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—hematologic cancer	3.77e-07	3.17e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—hematologic cancer	3.74e-07	3.15e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	3.74e-07	3.15e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—hematologic cancer	3.69e-07	3.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—hematologic cancer	3.58e-07	3.01e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—hematologic cancer	3.55e-07	2.98e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—hematologic cancer	3.46e-07	2.91e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—hematologic cancer	3.38e-07	2.84e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—hematologic cancer	3.3e-07	2.78e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—hematologic cancer	3.3e-07	2.78e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—hematologic cancer	3.26e-07	2.74e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—hematologic cancer	3.24e-07	2.72e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—hematologic cancer	3.23e-07	2.72e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.22e-07	2.71e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—hematologic cancer	3.11e-07	2.62e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—hematologic cancer	3.08e-07	2.59e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—hematologic cancer	3.06e-07	2.57e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.99e-07	2.51e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.83e-07	2.38e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—hematologic cancer	2.8e-07	2.35e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—hematologic cancer	2.79e-07	2.34e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.67e-07	2.25e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—hematologic cancer	2.64e-07	2.22e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	2.5e-07	2.1e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—hematologic cancer	2.5e-07	2.1e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.47e-07	2.08e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.44e-07	2.05e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.3e-07	1.94e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	2.28e-07	1.92e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—hematologic cancer	2.28e-07	1.91e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—hematologic cancer	2.13e-07	1.79e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—hematologic cancer	2.04e-07	1.72e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—hematologic cancer	2.03e-07	1.71e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—hematologic cancer	1.99e-07	1.68e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—hematologic cancer	1.88e-07	1.58e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—hematologic cancer	1.86e-07	1.57e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.5e-07	1.27e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—hematologic cancer	1.23e-07	1.03e-06	CbGpPWpGaD
